News

Article

Merck KGaA, Darmstadt, Germany, announces completion of Sigma-Aldrich Acquisition

Merck KGaA announces the completion of the acquisition of Sigma-Aldrich, a St. Louis-based life-sciences and technology company.

Merck KGaA, Darmstadt, Germany announced on Nov. 18, 2015, the completion of their acquisition of Sigma-Aldrich, a St. Louis-based life-science and technology company, according to a press release.

The $17-billion acquisition follows last week’s approval from the European Commission, the final antitrust condition required to close the Sigma-Aldrich transaction. 

The acquisition boosts Merck KGaA to around 50,000 employees in 67 countries worldwide.

In 2014, Merck KGaA’s life sciences division grossed a total of €4.6 billion (approximately $4.89 billion) in sales. With the addition of Sigma-Aldrich, the company expects a total gross of between €12.6 billion (approximately $13.4 billion) and €12.8 billion (approximately $13.61 billion) for 2015.

Merck KGaA announced the acquisition of Sigma-Aldrich in a September 2014 press release, saying this decision would allow them to increase their presence in the North American and Asian markets.

According to the company, the acquisition merged Merck KGaA’s existing life-sciences division, EMD Millipore, with Sigma-Aldrich, now MilliporeSigma.

Merck KGaA has made nearly €38 billion (approximately $40.4 billion) in acquisitions and divestments in the past 10 years, expanding their business in the areas of science, technology, healthcare, and life science. 

Source: Merck KGaA

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content